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Red blood cells (RBC) have been considered almost exclusively as a transporter of metabolic gases and
nutrients for the tissues. It is an accepted dogma that RBCs take up and inactivate endothelium-derived
NO via rapid reaction with oxyhemoglobin to form methemoglobin and nitrate, thereby limiting NO
available for vasodilatation. Yet it has also been shown that RBCs not only act as “NO sinks”, but exert an
erythrocrine function – i.e an endocrine function of RBC – by synthesizing, transporting and releasing NO
metabolic products and ATP, thereby potentially controlling systemic NO bioavailability and vascular
tone. Recent work from our and others laboratory demonstrated that human RBCs carry an active type 3,
endothelial NO synthase (eNOS), constitutively producing NO under normoxic conditions, the activity of
which is compromised in patients with coronary artery disease. In this review we aim to discuss the
potential role of red cell eNOS in RBC signaling and function, and to critically revise evidence to this date
showing a role of non-endothelial circulating eNOS in cardiovascular pathophysiology.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
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Nitric oxide (NO) is a short-lived signaling/regulatory product
of the endothelium that is critically important for vascular health
[1]. The ﬁrst biological activity attributed to NO was the ability to
induce relaxation of preconstricted aortic vascular preparations,
and for as long as its chemical nature remained unknown it was
deﬁned as “endothelium-derived relaxing factor” (EDRF)[2–4]. NO
is now recognized to play a fundamental role in the control of
vascular tone and blood ﬂow [5] and to represent a central
signaling entity in the cardiovascular system [6]; moreover, it is
also a critical player in neurotransmission [7], host defense and
inﬂammatory processes [8].
NO is enzymatically produced by NO synthases (NOS, EC
1.14.13.39), heme-containing proteins catalyzing the ﬁve-electron
oxidation of the guanidino nitrogen of L-arginine to NO and
citrulline. This process requires oxygen and a number of cofactors
including calcium, calmodulin, NADPH, ﬂavin mononucleotide
(FMN), ﬂavin adenine dinucleotide (FAD), and tetrahydrobiopterin
[6,9]. The proposed reaction mechanism involves electron transfer
from the ﬂavin-bindings site via calmodulin to the heme group,
where the oxidation of one of the guanidino nitrogens of L-arginine
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to the intermediate product, N-hydroxy-L-arginine takes place [10].
Tetrahydrobiopterin appears to be important in maintaining the
enzyme in its active dimeric form [9,10].
In mammals there are three distinct isoforms of NOS, encoded
by three different genes. The human loci are deﬁned as NOS1
(Gene ID 4842) coding for the neuronal nitric oxide synthase
(nNOS), NOS2 (Gene ID 4843) for the inducible nitric oxide
synthase (iNOS) and NOS3 (Gene ID: 4846) for endothelial nitric
oxide synthase (eNOS). Whereas iNOS typically produces high-
output NO levels and participates in host defense, inﬂammatory
stress and airway epithelial NO formation, the constitutively
expressed isoforms, nNOS and eNOS, are lower NO output systems
that are important for physiological processes such as neuronal
signaling, inhibition of the hemostatic system, vasodilation and
blood pressure control [9,10].
The constitutively expressed enzymes eNOS and nNOS are
activated after stimulation of speciﬁc receptors by various agonists
(e.g., acetycholine, bradykinin, serotonin, adenosine, ADP:ATP,
histamine, and thrombin), with consecutive increase of intracel-
lular free Ca2þ . The binding of Ca2þ to the Ca2þ/calmodulin
subunit of these proteins activates the enzyme to produce NO. In
vascular tissue, the binding of NO to the Fe2þ-heme of soluble
guanylyl cyclase (sGC) activates this enzyme to produce cyclic
guanosine-3-5-monophosphate (cGMP) from guanosine-5-
triphosphate (GTP). The signal is then transduced to downstream
elements of the signaling cascade, including cGMP-dependent
protein kinases, cGMP-gated cation channels, and cGMP-
regulated phosphodiesterase [11].
In healthy blood vessels, eNOS-derived NO contributes to the
regulation of blood ﬂow and blood pressure, is an inhibitor of
platelet activation and aggregation as well as leukocyte adhesion
and migration [12]. Furthermore, endothelial eNOS appears to
contribute to the formation of bioactive circulating NO metabolites
[13–17] (Fig. 1) that participate in important endocrine activities
such as hypoxic vasodilation, blood pressure regulation, gene
expression and cytoprotection following myocardial infarction
[18–27]. Mice genetically deﬁcient in endothelial nitric oxide
synthase (eNOS-/-) are hypertensive and have lower circulating
nitrite levels, demonstrating the importance of constitutively
produced NO to blood pressure regulation and vascular home-
ostasis [14,28–30].
Conventional wisdom holds that the pleiotropic effects of eNOS
are primarily determined by the enzyme located in the endothe-
lium. In addition to endothelial cells, most circulating blood cells –
including all main leukocyte subpopulations [31–35], platelet-rich
plasma [36], and circulating blood microparticles [37], but not
puriﬁed platelets [38,39] also carries eNOS transcript and/or
protein. Recent work from our laboratory demonstrated that RBCs
also carry a functional eNOS [32,40]. Production of NO by
hemoglobin-containing RBCs under normoxic conditions by red
cell eNOS, the expression of which is decreased in cardiovascular
disease [32,41], appears paradoxical in view of earlier reports
suggesting a major role of these blood cells in NO inactivation,
inviting a major rethink.
In this review we will discuss the potential role of red cell eNOS
in RBC signaling and function and summarize the evidence to date
that suggests a role for non-endothelial circulating eNOS in
cardiovascular pathophysiology.
Red blood cells in control of the vascular NO pool
It is an accepted dogma that RBCs take up and inactivate
endothelium-derived NO via rapid reaction with oxyhemoglobin
(oxyHb, FeIIO2Hb) to form methemoglobin (metHb, FeIIIHb) and
nitrate, thereby limiting NO available for vasodilatation.
FeIIO2HbþNO-FeIIIHbþNO3 ð1Þ
Yet it has also been shown that RBCs not only act as “NO sinks”
but synthesize, store, and transport NO metabolic products (Fig. 1),
and that hemoglobin plays a central role in these biochemical
processes [42]. Under hypoxic conditions in particular, it has been
demonstrated that RBCs induce NO-dependent vasorelaxation
{Cosby, 2003 #411;Webb, 2008 #448;Crawford, 2006 #518}.
Mechanisms of release and potential sources of NO in RBCs are
still a matter of debate, but candidates include iron–nitrosyl–
hemoglobin [44], S-nitrosohemoglobin [15,45,46], and nitrite
[47,48]. The latter may form NO either via deoxyhemoglobin
(deoxyHb, FeIIHb) [22,49] or xanthine oxidoreductase (XOR)-
mediated reduction [43], or via spontaneous [50] and carbonic
anhydrase-facilitated disproportionation [51]. Most of these pro-
cesses show a clear oxygen-dependence, and several are favored
by low oxygen tensions. The relative contribution of either
mechanism to NO formation varies with oxygen partial pressure
along the vascular tree [52,53].
In addition, RBCs are thought to contribute to the regulation of
systemic NO bioavailability by releasing ATP when subjected to
hypoxia or shear stress, which seems to be dependent on the
activation of erythrocytic pannexin-1 channels [54–56] inducing
eNOS-dependent vasorelaxation and an increase in blood ﬂow
[57–61].
Fig. 1. Upper panel: The expression of eNOS in the endothelium of the vessels
decreases along the vascular tree, while blood cell eNOS carried by all main blood
populations is equally distributed. Middle panel: In the blood compartment a
circulating pool of NO metabolites is formed and transported in plasma and RBC.
Bottom panel: NO can be synthesized enzymatically from L-arginine under normoxic
conditions in a reaction catalyzed by a NOS, and under hypoxic conditions from nitrite
by the nitrate reductase activity of proteins including deoxyhemoglobin (deoxyHb),
deoxymyoglobin (deoxyMb), xantine oxidoreductase (XOR), carbonic anydrase (CA),
and cytochrome C (cytC)/cytC-oxidase. eNOS, endothelial nitric oxide synthase; LNO2,
nitrated lipids; RSNO, nitrosothiols; RNNO, nitrosamines.
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The history of red cell eNOS
The presence of a NOS-like activity in RBCs had been a matter
of controversy for some time, and doubts about its functional
signiﬁcance, isoform identity and disease relevance had been put
forward by different authors.
Immunostaining of human, mouse, and rat RBCs or of RBC
membranes (“ghosts”) indicated that RBCs carry a protein contain-
ing epitopes of a NOS3 [62–65]. In some reports, a positive staining
with anti-iNOS antibodies [64,65] was detected, while others
suggested that RBCs might express a novel NOS isoform [62,64].
Enrichment of the protein from human and murine lysates by
cross-linking of speciﬁc antibody anti-eNOS to magnetic beads
allowed us to conﬁrm by mass spectrometry the chemical identity
of the protein as NOS3 isoform 1, i.e. the same protein that
is expressed in endothelial cells [32]. Further conﬁrmation of
identity was the absence of the protein in RBCs obtained from
eNOS-/- mice [66] and the Ca2þ/calmodulin dependent conversion
of L-arginine to citrulline by the isolated protein [32] and RBC
membrane preparations [66]. Thus, from these studies it is evident
that both human and mouse RBCs carry a catalytically active eNOS.
Doubts about the functional signiﬁcance of NOS activity in RBCs
are mainly linked to the fact that RBCs carry high concentrations of
oxyHb, corresponding to a concentration of 10 mM heme [42].
Considering that oxygenated hemoglobin is an highly efﬁcient NO
scavenger one might predict that eNOS-derived NO produced in the
red cell must be scavenged as soon as it is produced; according to
this logic, red cell eNOS should only have a limited, if any functional
signiﬁcance in adult RBCs. Yet, this is not what one ﬁnds “in real life”.
NOS activity in RBCs has been studied under normoxic conditions by
measuring the formation of NO and NO metabolites (nitrite, nitrate
and RXNO) in the supernatant of whole RBCs [40,63,67,68] and by
measuring the conversion of L-3H-arginine to L-3H-citrulline in the
presence of cofactors, i.e. NADPH, THB, Ca2þ/Calmodulin [69,70].
Addition of NOS inhibitors decreased accumulation of NO metabo-
lites [40,63,67] and citrulline production [69,70], while increasing
arginine availability by inhibition of arginase increased release of
nitrate [68]. However, two reports failed to measure citrulline
formation or NO metabolite accumulation from L-arginine in RBC
lysates [65] or changes in 15N/14N nitrite or nitrate ratio [71].
Nevertheless, another report conﬁrmed that human RBC converts
L-15N-arginine in L-15N-citrulline using liquid-chromatography tan-
dem mass spectrometry [41].
One wonders why there are so many discrepant data sets
regarding the presence and activity of an (e)NOS in RBCs. Some
discrepancy may be due to methodological issues encountered in
performing experiments with RBCs, but in some cases the dis-
crepancy rests with differences in interpretation rather than
experimental results. The main methodological issues encoun-
tered in working with RBCs comprise (but are not limited to) their
fragility as compared to other cells, accompanied by their depen-
dence on the presence of glucose as a sole source for intracellular
ATP, and the presence of overwhelming concentrations of hemo-
globin. The latter can pose a real challenge for biochemical or
enzymatic assays. Preparation of cell lysates, or membrane pre-
parations, deﬁned as “ghosts”, to get around this problem might
contribute to loss of cellular structures, critical protein–protein
interaction and cofactors important for catalytic activity [72].
Measuring changes in 15N/14N-nitrite or 15N/14N-nitrate ratios after
incubation with 15N L-arginine [71] in the presence of high
concentrations of hemoglobin may not necessarily reﬂect true
NOS activity because the chemistry of formation of nitrite and
nitrate from NO may be dependent on other competing reactions
involving NO/NO metabolites and oxy/deoxy/methemoglobin
(metHb, FeIIIHb) occurring, which could conceivably affect not
only NO but also nitrite and nitrate levels. These considerations
include, but are not limited to the oxyHb-dependent conversion of
NO and nitrite to nitrate [42], the presence of ceruloplasmin [73]
and/or other plasma proteins converting NO into nitrite, and the
enzymatic conversion of nitrite back to NO (for example catalyzed
by XOR [43]). Another factor to consider is the presence of arginase
in RBCs [65,68], competing for the NOS substrate L-arginine. Kang
et al. claimed that whole RBCs do not convert 3H L-arginine into
citrulline but rather into ornitine, and, therefore, suggested that
Metha et al. did not measure NOS activity, but arginase activity
instead [65]. Metha et al. responded by saying that Kang et al. used
RBC lysates instead of whole cells, thus loosing structural com-
partmentalized integrity of the cell [72]. More recent studies
showed that increase in L-arginine availability by inhibition of
arginase increase nitrate levels in the supernatant of whole blood
or RBC preparations [40,68], and that NOS inhibition on top of
arginase inhibition decrease it [68], indicating a cross talk between
the two enzymes.
Using ﬂow cytometry in combination with the NO-imaging
probe DAF-FM DA [74] we ﬁnd that all blood cells form intracel-
lular NO, with a rank order of monocytes4neutrophils4 lympho-
cytes4RBCs4platelets [32]. Constitutive normoxic NO formation
was abolished by NOS inhibition and intracellular NO scavenging,
conﬁrmed by laser-scanning microscopy and unequivocally vali-
dated by detection of the DAF-FM reaction product with NO using
HPLC and LC-MS/MS [32,74]. We found that isolated immunopre-
cipitated red cell eNOS is capable of producing 9.82 fmol/min
L-citrulline under optimal substrate/cofactor supply conditions and,
interpolating the areas of the DAF-FM-T related peaks observed in
DAF-FM-DA loaded RBCs, we estimated that the average concentra-
tion of DAF-FM-T in these samples was 64712 nM (n¼19). Assum-
ing the reaction stoichiometry to be 1:1, we therefore estimate that
the amounts of total NO and/or nitrosating equivalents produced
by a single RBC within 30 min at RT correspond to at least
3.27106 fmoles under nomoxic conditions.
A central challenge of any hypothesis proposing a role of RBC-
derived NO in human (patho)physiology is to understand how NO
formed by these cells can escape irreversible dioxygenation reac-
tion with oxyHb (reaction 1), which is a very rapid reaction.
A “metabolon complex” of deoxyHb, AE/band 3, carbonic anhydrase,
aquaporin, and Rh-protein channels was proposed to explain
Fig. 2. Potential role of red cell eNOS in signalling. L-arginine is imported into the
RBC via the cationic amino acid transporters yþ/CAT and/or yþL. Both localization
of eNOS on the cytoplasmic side of the RBC membrane and protein-protein
interactions may play a central role in effectively separating eNOS from arginase,
as well as NO production from NO scavenging by oxyhemoglobin (oxyHb). Local
formation of methemoglobin (metHb) by reaction of eNOS-derived NO may protect
further produced NO from degradation by oxyHb, allowing NO to interact with
target proteins in the immediate vicinity of eNOS to exert intracellular signaling
function, leading to activation of NO signaling pathways. An example of such a
target might be the Pannexin-1 channel.
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nitrite protonation and may serve to facilitate the export of NO or
its metabolites [75]. The localization of eNOS-immunoreactivity on
the cytoplasmic side of the RBC membrane, as detected by
immunogold-labeling and electron microscopy imaging [40], sup-
ports the notion that the RBC membrane may play a central role in
this process, possibly by effectively separating NO production,
signaling and scavenging machinery from one another by com-
partmentalization. Local formation of metHb by reaction of eNOS-
derived NO may protect further produced NO from degradation by
oxyHb, allowing NO to interact with target proteins in the
immediate vicinity of eNOS to exert intracellular signaling func-
tion, leading to activation of NO signaling pathways (Fig. 2). An
example of such a target might be the Pannexin-1 channel, which
has been shown to be regulated by nitrosation reactions [76]. The
observation that NO formation can be detected in the vicinity of
abundant oxyHb would seem to warrant a careful reassessment of
the universally accepted paradigm that RBC in normoxic condi-
tions should be considered just a “sink” of NO.
Pathophysiological signiﬁcance of red cell eNOS–control
of erythrocrine function?
The ability of RBCs to secrete bioactive molecules including NO
metabolites and ATP appears to be an important aspect of their
function. This “erythrocrine function1”, characterizing the exocrine
activity of RBC, might play an important role in pathophysiology.
Some evidence of a role of red cell eNOS in controlling the
erythrocrine function exists from in vitro studies. NOS inhibitors
abolish the anti-platelet effects of RBCs in vitro [40,69] and
decrease the level of NO products released by isolated RBCs
[13,40,63]. Perfusion of isolated lungs with washed RBCs in the
presence of L-NAME increased pulmonary vascular resistance, as
compared to control cells without inhibitor [78]. Perfusion with
whole blood or washed RBCs in normoxia protect isolated per-
fused hearts from ischemia/reperfusion injury in a NOS and
arginase-dependent fashion [68,70]. Moreover, both the presence
of eNOS in blood and the inhibition of arginase to increase
L-arginine availability reduces infarct size and left ventricular
dysfunction in an ex vivo model ischemia/reperfusion [68].
Other studies suggest that activity of a red cell eNOS may be
involved in the regulation of RBC deformability [40,79,80]. Inter-
estingly, a link between RBC deformation and ATP release was also
demonstrated [56,57] and nitrite was shown to induce ATP release
under hypoxic conditions from RBC [81], probably by releasing NO.
Considering this data, it is tempting to speculate that red cell eNOS
might be involved in regulating ATP release under normoxic
conditions. However, a link between red cell eNOS-derived NO
production and ATP is still awaiting experimental veriﬁcation.
In vivo evidence indicating a red cell eNOS-dependent control
of this erythrocrine function and its pathophysiological conse-
quences in vivo was derived by analyzing the phenotype of
chimera obtained by bone marrow transplantation from eNOS-/-
mice into lethally irradiated wild type (WT) mice (Fig. 3) [66,82].
These mice carry blood cells that lack eNOS, and are characterized
by a signiﬁcant decrease in circulating nitrite and nitrate levels in
blood, as well as higher blood pressure, as compared to the
controls [66]. After depleting these mice from leukocytes or
platelets, the differences between the chimeras lacking blood cell
eNOS and the wild type counterpart persisted. These results
demonstrated for the ﬁrst time that beside the enzyme that is
expressed in the endothelium, also circulating blood cell eNOS
plays a role in the control of vascular tone and blood pressure;
furthermore, they suggest that RBCs, the most abundant cell
population in blood, might be involved in mediating those effects.
If eNOS in blood indeed contributed to blood pressure regula-
tion and nitrite production, then it is likely to also have effects
under regenerative conditions, such as tissue repair following
myocardial ischemia or stroke. In an acute model of myocardial
ischemia/reperfusion we found that chimeras lacking blood cell
eNOS had increased infarct size, resulting in decreased ejection
fraction and increased end systolic volume after 60 min ischemia
and 24 h of reperfusion [82]. Application of the NOS inhibitor
ethylenethiourea (ETU) during ischemia and the ﬁrst 5 min of
reperfusion was associated with larger infarct size in mice carrying
eNOS in blood, whereas infarct size in mice lacking blood cell
eNOS was unaffected [82]. RBCs from chimera lacking blood cell
eNOS have decreased deformability [82], which may lead to
decreased perfusion capacity of blood.
Taken together, these results show that circulating blood cell
eNOS plays a role in the control of the circulating pool of NO
metabolites, and further suggests a modulating role in ischemia/
reperfusion injury (Fig. 4). An earlier study by Ii and colleagues [83]
may also be of relevance in this context. That study evaluated similar
cross-transplantation experiments with bone marrow recipient mice
subjected to experimental myocardial infarction. Cardioprotection
was observed in the eNOS-/- mice receiving WT bone marrow, which
at the time was ascribed to NO released by EPCs that had been
incorporated into the ischemic myocardium. However, in that study
only a small percentage of EPCs are incorporated in the ischemic
myocardium, suggesting that the cardioprotection may have also
originated from circulating blood cell-derived eNOS activity or nitrite.
The blood cell(s) populations responsible for cardioprotection have
still to be identiﬁed.
The use of bone marrow chimeric mice to analyze the patho-
physiological role of red cell eNOS has profound methodological
limitations, including irradiation-dependent activation of inﬂam-
matory pathways (which may increase the expression of an
inducible NOS), the possibility of protein transfer from the blood
to the endothelium (due to housing of circulating endothelial
progenitor cells), the presence of low levels of circulating blood
cells from the recipient, and – most importantly – the lack of
erythroid lineage targeting speciﬁcity. Therefore, in these studies
we could not discriminate the blood cell population(s) carrying
eNOS that might affect nitrite levels, the tone of resistance arteries
or exerting cardioprotective effects. These limitations can be only
overcome by applying more speciﬁc genetic approaches, i.e. by
using conditional mutant mice lacking or expressing eNOS in the
erythroid lineage only.
Nevertheless, these are the ﬁrst studies to deﬁnitively establish
a role for circulating blood cell eNOS in the regulation of nitrite
homeostasis, blood pressure and cardioprotection in an ischemia/
reperfusion injury model under physiological conditions, and
point to a possible role of red cell eNOS in this context. These
ﬁndings challenge our conventional perspectives on NO and NO
metabolite/nitrite signaling in blood, suggesting a more holistic
regulation of cardiovascular homeostasis, with contributions from
both the endothelium and circulating blood cells. In addition to
the involvement of NO itself, other groups have demonstrated that
circulating nitrite is a signaling molecule [18], and can be reduced
to form NO, and thereby contribute to the regulation of hypoxic
vasodilation, cytoprotection following ischemia/reperfusion
events, adaptation to hypoxia and vascular angiogenesis
[21,24,26,53,84–91].
1 Note: The ability RBCs to release analgesic peptides was deﬁned as “erythro-
crine”, or exocrine activity of erythrocytes [77]. In this review we adopt this term in
a more general sense to deﬁne the ability of RBCs to secrete signaling entities or
transmitter molecules including amino acids, nucleotides gases and other media-
tors able to participate in cell-cell communications as well as to control biochem-
ical processes.
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Thus, it is likely that both, direct NO formation and signaling as
well as nitrite-mediated signaling, contribute to the beneﬁcial
effects of blood cell eNOS in blood pressure control and
cardioprotection (Fig. 4). The existence of a functional blood-
borne eNOS opens the door to studies addressing the function
and dysfunction of blood eNOS in health and disease, such as a
role in red blood cell enzymopathies, hemoglobinopathies and
membranopathies, as well as in infectious diseases such as
malaria.
Impaired red cell eNOS function in cardiovascular disease
Impaired endothelial function, decreased eNOS activity, and/or
NO bioavailability are conditions strongly related to cardiovascular
disease [13,16]. Perhaps one of the most surprising results from
our more recent studies [32], which have recently been conﬁrmed
by an independent group [41], is that expression and activity of
circulating eNOS in RBCs [32], or plasma microparticles [37] is
decreased in patients with endothelial dysfunction as compared to
healthy controls. Thus, red cell eNOS expression and activity is
decreased in patients with coronary artery disease as compared to
age matched healthy controls and signiﬁcantly correlates with
ﬂow-mediated dilation, a diagnostic marker of endothelial func-
tion and eNOS activity [32]. Similarly, eNOS levels and activity are
decreased in microparticles from patients with peripheral arterial
occlusive disease as compared to young healthy controls [37].
Moreover, eNOS could not be detected in circulating angiogenic
cells from coronary artery disease (CAD) patients, and both
chemokinesis and chemotaxis to VEGF were decreased compared
with healthy circulating angiogenic cells [92]. Thus, a systemic
circulating eNOS deﬁciency and/or dysfunction appears to prevail
in patients with cardiovascular disease the consequences of which
are not limited to impaired vascular function, but may also affect
function of blood cells and vascular homeostasis.
Clinical perspective
RBCs are typically considered as shuttles of respiratory gases
and nutrients for tissues, less so as compartments important to
vascular integrity. However, RBC size distribution [93–95], number
[96–99] and integrity [100] appear to profoundly affect cardiovas-
cular morbidity and mortality as demonstrated in recent clinical
Fig. 3. Creation in vivo chimera models for studying the role of blood cell eNOS. To analyze the role of blood cell eNOS we created chimeras carrying eNOS in the blood only
(group II) or lacking eNOS in the blood only (group III) and respective controls (groups I, IV) by cross-transplanting the bone marrow of wild type (WT) or eNOS knockout
(eNOS-/-) mice into lethal irradiated mice. We found that also blood cell eNOS play a role in control of vascular tone and cardioprotection.
Fig. 4. Pathophysiological signiﬁcance of red cell eNOS. An accumulating body of
evidence identiﬁes RBCs as active contributors to vascular homeostasis and
cardioprotection. These effects might be due to the ability of RBCs to secrete
vasoactive and cardioprotective molecules, a property which we here deﬁne as
erythrocrine function, and might be dependent on the activity of red cell eNOS.
Further studies are required to unravel its nature, regulation and pathophysiolo-
gical signiﬁcance.
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studies with large patients cohorts. Patients with CAD and con-
comitant anemia have a poorer prognosis after myocardial infarc-
tion, percutaneous coronary intervention, and coronary artery
bypass grafting, and are more prone to developing heart failure
with fatal outcomes [96–98]. Surprisingly, erythropoietin treat-
ment fails to improve diagnosis [99], indicating that a compro-
mised gas exchange/nutrient transport capacity of blood is
insufﬁcient to explain this outcome. In a cohort of 40,000 patients
baseline levels of hemoglobin have been found to correlate with
mortality after myocardial infarction according to a
J-shaped relationship in that a mild decrease in baseline hemo-
globin concentration (12–14 g/l) corresponds to a strong increase
in mortality after acute cardiovascular events [101]; these associa-
tions are difﬁcult to explain by a decrease in the capacity of oxygen
delivery to tissues.
The issues surrounding appropriate storage of blood (blood
banking) and the negative effects associated with the transfusion
of “old” blood or RBCs preparations have increasingly attracted
attention over the years and become a matter of scientiﬁc discus-
sion and somewhat of a “hot topic” in translational research lately
[102,103]. In a retrospective study including 6000 patients Koch
et al. showed that subjects receiving RBC units older than 2 weeks
were more likely to die than subjects receiving newer blood [100].
Although this study is not without controversy [102], the dama-
ging effects of transfusion with older blood units had already been
observed in earlier retrospective studies [103,104]; there, however,
they have been attributed to changes in RBC oxygen transport
capacity, RBC fragility and hemolysis, and pro-inﬂammatory
effects. Basic science studies have shown that increased mem-
brane fragility of “old” RBCs may also lead to formation of
hemoglobin-rich microparticles [105–107], as well as a decrease
in intracellular ATP, NO metabolites, and L-arginine, and an
increase in reactive oxygen species and oxidative damage [108–
110], thus potentially affecting erythrocrine function. This leads to
an overall decrease in RBC deformability, a decrease in the RBC
oxygen-carrying capacity and tissue perfusion, and importantly to
systemic effects of free/microparticle hemoglobin-derived
decrease in NO bioavailability, including endothelial dysfunction,
increases in blood pressure, vasospasm and a prothrombogenic
milieu. Whether and how red cell eNOS activity and/or signaling is
involved in changes of RBC function in disease has not been
investigated so far. While red cell eNOS does not seem to play a
role in RBC membrane fragility in either fresh or stored blood
[111], a decrease of red cell eNOS activity may still be involved in
the regulation of RBC lifespan [112] and RBC deformability
[40,79,80]. Future studies are required to address these important
questions and close those open loops.
Summary and outlook
An accumulating body of evidence demonstrates that not only
endothelial cells, but also blood cells contribute to the NO-
dependent regulation of vascular homeostasis, and identiﬁes RBCs
as active contributors to vascular homeostasis and integrity. These
effects might be due to the ability of RBCs to secrete vasoactive
and cardioprotective molecules, a property, which we here deﬁne
as erythrocrine function. Further studies are required to unravel its
nature, regulation and pathophysiological function.
Taken together, a picture emerges according to which RBCs
contribute to vascular homeostasis, independent of their “classical
role” as transporters of oxygen, energy substrates and nutrients.
Given the contribution RBCs make to the circulating NO pool, their
role in hypoxic vasodilation and their overall signiﬁcance for organ
protection further studies would seem to be warranted to address
their functional signiﬁcance for the regulation of cardiovascular
function in health and disease.
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